I
n the gastrointestinal tract, cell migration is essential in healing of superficial epithelial injury, cell differentiation, and maintenance of barrier function. 1 However, unchecked migration of cells can give rise to invasive or metastatic gastrointestinal diseases. 1 Lysophosphatidic acid (LPA) is a growth factor-like phospholipid that has the potential to induce cancer progression by stimulating cell proliferation and protecting cancer cells from chemotherapeutic treatment. 2, 3 LPA mediates diverse effects through its cognate receptors that include at least 5 members of the G-protein-coupled receptor (GPCR) superfamily, LPA 1 -LPA 5 . 4 Increased expression of LPA 2 in several types of cancer is of tremendous clinical interest given the tumor-promoting activity of the aberrant LPA signaling axis. 5, 6 Recently, we showed that LPA 2 deficiency protected mice from colitis-induced colon cancer. 7 GPCRs associate not only with G proteins, but with various other proteins that can regulate receptor activity. 8 LPA 2 contains a postsynaptic density 95, discs large, and zonula occludens-1 (PDZ) binding motif at the carboxyl terminal end that enables interaction with multiple PDZ scaffold proteins, including Na ϩ /H ϩ exchanger regulatory factor 2 (NHERF-2), membrane-associated guanylate kinase with inverted orientation-3 (MAGI-3), neurabin, and PDZ-Rho guanine nucleotide exchange factors. 6,9 -11 NHERF-2 enhances LPA 2 -dependent cell proliferation and gene expression, 6 ,9 whereas MAGI-3 or PDZ-Rho guanine nucleotide exchange factor interaction with LPA 2 enhances receptor-mediated activation of RhoA. 10, 11 However, the pathophysiological effects of these interactions have not been studied. In cells that express more than one LPA 2 -interacting PDZ scaffold, it is not known if LPA 2 regulation by the PDZ proteins is antagonistic, additive, or synergistic. In an effort to understand the functional role of MAGI-3 and how multiple scaffold proteins in a given cell compete or coordinate to modulate the biological effects and signaling pathways elicited by LPA 2 , we investigated functional modulation of LPA 2 by NHERF-2 and MAGI-3 in colon cancer cells.
Materials and Methods Cells
HCT116 and SW480 human colon cancer cells were grown and transfected as previously described. 12 pcDNA3.1 harboring MAGI-3 or NHERF-2 was described previously. 6, 12 Knockdown of MAGI-3, NHERF-2, or LPA 2 was performed as previously described. 11 Stable expression of LPA 2 was achieved by using retroviral pLPCX harboring vesicular stomatitis virus glycoproteintagged LPA 2 , pLPCX/VSVG-LPA 2 , or pLPCX (Roche, Indianapolis, IN). Unless otherwise stated, cells were serumstarved for 24 hours followed by exposure to 1 mol/L LPA.
Antibodies
See the Supplementary Materials and Methods section for more detail.
Animals
Mouse tissues were generated in the previously reported studies. 7 Mice were maintained and experiments were performed under the institutional guidelines of Emory University.
Cell Invasion and Migration
An in vitro invasion assay was performed in BioCoat Matrigel invasion chambers (BD Bioscience, San Jose, CA). HCT116 or SW480 cell suspensions (5 ϫ 10 5 cells/mL) were placed into the upper chamber in 0.5 mL of serum-free medium. The lower compartment was filled with serum-free medium containing 1-10 mol/L LPA (prepared in phosphate-buffered saline [PBS] containing 0.1% bovine serum albumin; Avanti Polar Lipids, Alabaster, AL) or with an inhibitor. After incubation for 24 hours, cells that had migrated to the lower surface of the filters were fixed in acetone for 5 minutes at room temperature and visualized with a H&E staining method. The staining was viewed with an Axioskop 2 plus microscope (Zeiss, Thornwood, NY). Cells were counted in several fields of triplicate membranes. For the migration assay, the confluent monolayer was scraped with a pipette tip, washed with PBS, and incubated in culture medium supplemented with 10% fetal bovine serum for 24 hours. The cell migration was observed by a Nikon Ti-U microscope (Melville, NY).
Inositol Phosphate Generation
Cells were labeled with 1 Ci of myo-[ 3 H]-inositol (NEN Life Sciences, Boston, MA) and processed as previously described. 13 See the Supplementary Materials and Methods section for detail.
Western Immunoblot and Immunoprecipitation
Western blotting and immunoprecipitation was performed as previously described. 11 See the Supplementary Materials and Methods section for details.
Cell Surface Expression Assay
The expression level of LPA 2 on the plasma membrane was quantified as described. 14 See the Supplementary Materials and Methods section for details.
Immunohistochemical Analysis of Colon Tissue Array
Human colon tissue array slides (IMH-359) were purchased from Imgenex (San Diego, CA). Immunohistochemical labeling was performed as previously described. 7 The expression levels of MAGI-3 and NHERF-2 in tissue microarrays were quantified according to the published method. 15 See the Supplementary Materials and Methods section for details.
[ 35 S]Guanosine Triphosphate-␥-S Binding Assay
G-protein activation was determined by measuring the binding of the nonhydrolysable analog [ 35 S]guanosine triphosphate (GTP)-␥-S to G␣ subunits according to the method of Lazareno and Birdsall. 16 
Statistical Analysis
Results are presented as the mean Ϯ standard error. Statistical significance was determined by the Student t test as post hoc tests after 1-way analysis of variance using the SPSS program (Chicago, IL).
Results

NHERF-2 and MAGI-3 Reciprocally Regulate LPA 2 -Mediated Cellular Functions
To determine the role of MAGI-3 and NHERF-2, we used human colon cancer HCT116 cells, which express NHERF-2 and MAGI-3. We have shown previously that LPA 2 is the major LPA receptor in Caco-2 and other colon cancer cells. 6 Consequently, silencing of LPA 2 expression abrogated LPA-induced migration of HCT116 cells, whereas overexpression of LPA 2 enhanced cell migration (Figure 1A and B; Supplementary Figure 1A and B). Consistent with previous reports that NHERF-2 enhances LPA 2 -evoked cell proliferation and gene expression, overexpression of NHERF-2 increased cell migration ( Figure 1C; Supplementary Figure 1C) , whereas knockdown decreased cell migration ( Figure 1D ; Supplementary Figure 1D ). 6, 9 In contrast, overexpression of MA-GI-3 in HCT116 cells suppressed LPA-induced cell migration ( Figure 1C ; Supplementary Figure 1C) , whereas MAGI-3 knockdown resulted in the opposite effect (Figure 1D ; Supplementary Figure 1D) .
Next, the effects of NHERF-2 and MAGI-3 on the invasive capacity of colon cancer cells were determined by a Matrigel assay. Invasion of HCT116 cells was stimulated with increasing concentrations of LPA, which was potentiated when NHERF-2 was overexpressed ( Figure  1E ; Supplementary Figure 1E) . In contrast, MAGI-3 in-hibited LPA-mediated HCT116 cell invasion ( Figure 1E ; Supplementary Figure 1E ). The inhibitory effect of MA-GI-3 was similarly observed in SW480 cells, which endogenously express NHERF-2 and MAGI-3 ( Figure 1F ; Supplementary Figure 1F ). These results collectively show that NHERF-2 and MAGI-3 reciprocally regulate LPA 2 -mediated cellular functions.
MAGI-3 Negatively Regulates NHERF-2 Binding to LPA 2 and Interacts With Phospholipase C-␤3
NHERF-2 and MAGI-3 bind to the same carboxyl terminal PDZ binding motif of LPA 2 . 6, 9, 11 We explored the possibility that MAGI-3 might inhibit LPA 2 -mediated effects by interfering with NHERF-2 binding to LPA 2 . In HCT116/LPA 2 cells, LPA 2 co-immunoprecipitation with NHERF-2 was stimulated by LPA, indicating that LPA enhanced the LPA 2 -NHERF-2 interaction ( Figure 2A LPA 2 has an intrinsic ability to activate phospholipase C (PLC) to generate diacylglycerol and inositol 1,4,5-triphosphate. The physiological significance of PLC activation is shown in Supplementary Figure 2 , in which the LPA-induced invasion of HCT116 cells was abrogated by the presence of the PLC inhibitor U73122. Given the opposing effects of MAGI-3 and NHERF-2, we examined whether NHERF-2 and MAGI-3 differentially regulated LPA 2 -mediated PLC signaling. Figure 2C shows that LPA stimulates total inositol phosphate accumulation, which was enhanced by overexpression of NHERF-2. In comparison, expression of MAGI-3 in HCT116 ( Figure 2D ) or SW480 cells (data not shown) decreased LPA 2 -mediated PLC activity. The negative role of MAGI-3 was corroborated by knockdown of MAGI-3, which enhanced LPA 2 -mediated PLC activation ( Figure 2E ).
To determine whether the MAGI-3-dependent decrease in PLC activity is specific for LPA 2 , we examined activation of PLC activity by purinergic signaling. We have shown previously that NHERF-2 enhances purinergic P2Y receptor activation. 17 On the contrary, overexpression of MAGI-3 attenuated adenosine triphosphateinduced PLC activation, whereas a significant increase in inositol phosphate accumulation resulted from MAGI-3 knockdown (Supplementary Figure 3A and B). These results suggest that the ability of MAGI-3 to be a negative regulator of PLC activity is not unique to LPA 2 activation.
It was shown previously that PLC-␤3 binds to NHERF-2, 18 but the status of PLC interaction with MAGI-3 has not been reported. Therefore, we wondered whether the decreased PLC activity might be caused by the inability to bind PLC-␤ by MAGI-3. We co-expressed V5-MAGI-3 and each of Flag-tagged PLC-␤ isoforms, PLC-␤1-4, in HCT116 cells, followed by immunoprecipitation of V5-MAGI-3. Figure 2F shows that MAGI-3 specifically co-immunoprecipitated PLC-␤3, but not other PLC-␤ isoforms, identically recapitulating the NHERF-2 interaction with PLC-␤. Therefore, because both NHERF-2 and MAGI-3 specifically interact with PLC-␤3, differential PLC interactions could not explain why MAGI-3 and NHERF-2 exert opposing functional effects.
Because NHERF-2 potentiates PLC activity, 18 we hypothesized that MAGI-3 might inhibit PLC activity by interfering with the association of NHERF-2 and PLC-␤3. To test this possibility, we examined the effect of MAGI-3 knockdown on the NHERF-2-PLC-␤3 interaction. Figure  3A shows that knockdown of MAGI-3 increased the PLC-␤3-NHERF-2 association. Conversely, NHERF-2 knockdown augmented PLC-␤3 interaction with MAGI-3 ( Figure 3B ), revealing that NHERF-2 and MAGI-3 competitively interact with PLC-␤3. To address whether the LPA 2 -PLC-␤3 association is dependent on the presence of a specific PDZ protein, we determined the amount of PLC-␤3 complexed with LPA 2 when either MAGI-3 or NHERF-2 was knocked down. Surprisingly, we found that the amount of PLC-␤3 co-immunoprecipitated with LPA 2 was not modulated significantly by knockdown of either MAGI-3 or NHERF-2 ( Figure 3C and D) . The possibility that PLC-␤3 tethers to LPA 2 by a protein other than NHERF-2 or MAGI-3 was eliminated by simultaneous knockdown of NHERF-2 and MAGI-3, which evidently decreased the amount of PLC-␤3 bound to LPA 2 ( Figure 3E ). These results imply that MAGI-3 functions in the same manner as NHERF-2 in bridging LPA 2 and PLC-␤3, and that the total amount of PLC-␤3 associated with LPA 2 is independent of which of the 2 PDZ scaffolds are bound to the receptor.
MAGI-3 and NHERF-2 Differentially
Regulate LPA 2 Coupling With G␣ q and G␣ 12 , and LPA 2 Stability
Having shown that the amount of receptor-associated PLC-␤3 is unaffected by NHERF-2 or MAGI-3, we sought to determine whether the decreased PLC activity in the presence of MAGI-3 could be explained by inefficient coupling of the G␣ protein relative to NHERF-2. To this end, we measured LPA-dependent binding of the nonhydrolyzable GTP analogue, GTP-␥-S, which measures the total amount of agonist-induced G-protein activation. As expected, GTP-␥-S binding was increased in response to LPA (Supplementary Figure 4A) . However, overexpression of neither NHERF-2 nor MAGI-3 significantly altered the GTP-␥-S binding ( Supplementary Figure 4B) , implying that the differential regulation of PLC activation is not caused by a globally altered amount of G-protein binding.
However, it is possible that different G proteins can associate with LPA 2 when either NHERF-2 or MAGI-3 is co-expressed. To address this, HCT116/LPA 2 cells were treated with LPA and the association of LPA 2 with G proteins, G␣ q , G␣ i , and G␣ 12 , that are known to be activated by LPA was determined. Figure 4A shows that G␣ q and G␣ 12 , but not G␣ i , co-immunoprecipitated with LPA 2 , and the binding of G␣ q and G␣ 12 to LPA 2 was acutely stimulated by LPA. In the next experiment, we determined whether NHERF-2 and MAGI-3 interact with the same or different G proteins by immunoprecipitating NHERF-2 or MAGI-3 from HCT116/LPA 2 cells. Figure  4B shows that NHERF-2 (left panel) co-immunoprecipitated G␣ q , but not G␣ 12 , whereas MAGI-3 (right panel) co-immunopreciated both G␣ q and G␣ 12 . Subsequently, knockdown of MAGI-3 potentiated G␣ q association with Figure 4C ). On the contrary, knockdown of NHERF-2 increased the amount of G␣ 12 found in the complex with MAGI-3 ( Figure 4D ). The association of G␣ q and G␣ 12 with LPA 2 was reproduced with overexpression of MAGI-3 ( Figure 4E ), whereas, in cells overexpressing NHERF-2, co-immunoprecipitation of G␣ q with LPA 2 was stimulated by LPA, but the LPA 2 -G␣ 12 association was decreased with LPA treatment. The data imply that NHERF-2 enhances PLC activity by potentiating the G␣ q -PLC pathway, whereas MAGI-3 diverts receptor signaling between G␣ q and G␣ 12 .
NHERF-2 (
Receptor internalization or expression can be altered by scaffold proteins. 8 By using a luminometer-based cell surface assay, we did not see any evidence for LPA-mediated LPA 2 internalization. However, the amount of LPA 2 in the plasma membrane was decreased significantly with NHERF-2 knockdown ( Figure 4F ). On the contrary, MA-GI-3 knockdown had no effect on surface expression of LPA 2 . Simultaneous silencing of NHERF-2 and MAGI-3 reduced LPA 2 surface expression to a similar extent as that seen with NHERF-2 knockdown alone. Thus, our data reveal that NHERF-2 potentiates LPA 2 -elicited activities by stabilizing LPA 2 surface expression together with promotion of G␣ q -PLC signaling, whereas MAGI-3 attenuates LPA 2 signaling by diverting between G␣ q -and G␣ 12 -dependent pathways.
MAGI-3 Inhibits LPA-Induced Activation of Nuclear Factor-B and C-Jun N-Terminal Kinase
Nuclear factor-B (NF-B), a pleiotropic transcription factor, plays an important role in inflammation and carcinogenesis, and its activation by LPA via PLC has been shown in other cell types. 19 To further understand the mechanism whereby MAGI-3 alters signaling by LPA 2 , we examined the effect of LPA on NF-B in HCT116 cells and whether MAGI-3 could modulate NF-B activation. LPA increased the level of inhibitory kappa B␣ (IB␣) phosphorylation and the nuclear translocation of NF-B p65 ( Figure 5A and B, left panels) . In comparison, MAGI-3 knockdown increased IB␣ phosphorylation and nuclear translocation of NF-B p65 ( Figure 5A and B, right panels) .
In addition to the activation of NF-B, activation of c-Jun N-terminal kinase (JNK) often is associated with cell migration-related events, such as cytoskeletal rearrangement and cell motility. 20 LPA increased phosphorylation of JNK and c-Jun, which was potentiated by knockdown of MAGI-3 ( Figure 5C and D) . In contrast, activation of other protein kinases, such as Akt and p38, by LPA was not appreciably affected by changes in MA-GI-3 expression (data not shown). The role of NF-B, JNK, and protein kinase C (PKC) in LPA-mediated cell invasion was assessed by using NF-B essential modulator (NEMO) binding domain peptide, SP600125, and Gö6976, an inhibitor of conventional PKCs, to inhibit NF-B, JNK, and PKC, respectively. All the inhibitors blocked HCT116 cell invasion, indicating the involvement of PKC, NF-B, and JNK in cell invasion (Supplementary Figure 5A ).
To grasp the relationship between NF-B, JNK, and PLC activation induced by LPA, we examined phosphorylation of NF-B and JNK in the presence of inhibitors (Supplementary Figure 5B and C) . Phosphorylation of IB and JNK was blocked by U73122, but not by SP600125. Surprisingly, NEMO binding domain peptide inhibited JNK phosphorylation, indicating that NF-B stimulates JNK. Moreover, LPA-induced activation of cJun was inhibited by Gö6976 (Supplementary Figure 5D) . The sequences of putative signaling pathways are summarized in Figure 5E .
To further correlate LPA 2 with the NF-B pathway, we examined the phosphorylation status of IB␣ in intestinal tumors of LPA 2 -deficient (Lpar2 Ϫ/Ϫ ) mice that recently were reported by us. 7, 21 The phosphorylation level of IB␣ was increased in adenomas of Apc Min/ϩ compared with normal epithelial cells of wild-type mice (Supplementary Figure 6A) . In comparison, a loss of LPA 2 expression in Apc Min/ϩ (Apc Min/ϩ / Lpar2 Ϫ/Ϫ ) mice significantly decreased IB␣ phosphorylation. 21 Similarly, a loss of LPA 2 reduced IB␣ phosphorylation levels in tumors induced by azoxymethane and dextran sodium sulfate (Supplementary Figure 6A) . 7 
MAGI-3 and NHERF-2 Expression Are Altered in Human Colon Cancer
The differential roles of MAGI-3 and NHERF-2 in LPA-induced oncogenic effects prompted us to examine the expression levels of MAGI-3 and NHERF-2 in intestinal tissues. We first compared expression of these scaffolds in the intestine of wild-type and Apc Min/ϩ mice. The expression level of MAGI-3 was lower in intestinal adenomas of Apc Min/ϩ mice compared with normal intestinal tissue, whereas NHERF-2 showed a reverse pattern (Figure 6A) . The differential levels of MAGI-3 and NHERF-2 expression were further shown in human colon tissue arrays. Labeling of MAGI-3 was significantly lower in adenocarcinoma tissues in the ascending, transverse, and sigmoid colon, as compared with the prominent labeling in the plasma membrane and junctional membrane of normal colonocytes ( Figure 6B, left panels) . The immunostaining scores of MAGI-3 based on the intensity and proportion of stained cells gradually decreased from stage II through IV ( Figure 6C, left panels) . In contrast, NHERF-2 expression was up-regulated in human colon cancer tissues compared with healthy tissues ( Figure 6B  and C, right panels) . Even though the biological functions of MAGI-3 and NHERF-2 probably are not limited to the LPA-induced effects, the decreased MAGI-3 expression as well as the increased NHERF-2 expression in adenocarcinomas correlate well with the opposing roles of MA-GI-3 and NHERF-2 in LPA 2 -elicited cellular functions.
Discussion
The role of LPA signaling in the progression of cancer is an active area of study. Since the initial demonstration of the effect of LPA on cell proliferation, the identification of LPA as the ovarian-cancer activating factor in malignant ascites together with the finding of increased levels of LPA in ovarian and other gynecologic cancers have heightened the relevance of LPA to cancer. [22] [23] [24] The recent report that free fatty acid generation in cancer cells produces oncogenic lipids, such as LPA and prostaglandin E2, offers provocative implication for a role of LPA in linking obesity to tumorigenesis. 25 The tumorigenic effects of LPA primarily are mediated by the activation of LPA 2 , which is up-regulated in ovarian, colon, breast, prostate, uterus, and testis cancer. 5, 6, 26 Consistently, LPA 2 messenger RNA expression was increased significantly in adenomas of Apc Min/ϩ mice compared with nondysplastic intestinal tissue. 7, 21 In the present study, our data showed that the signaling and functions of LPA 2 are reciprocally modulated by the dynamic and coordinated interaction of 2 PDZ scaffold proteins, NHERF-2 and MAGI-3.
NHERF-2 is a known positive regulator of LPA 2. The interaction of NHERF2 with LPA 2 enhanced LPA-induced cell proliferation, cyclooxygenase-2 expression, interleukin-8 secretion, and anti-apoptotic property of colon cancer cells against chemotherapy. 6, 9, 27 Consistent with earlier findings, the positive effects of NHERF-2 on LPA 2 signaling are recapitulated in the present study using HCT116 and SW480 cells. On the other hand, apart from its interaction with Frizzled, ␤ 1 -adrenergic receptor, phosphatase with tensin homology mutated in multiple advanced cancers (PTEN/MMAC), and receptor tyrosine phosphatase-␤, the functional role of MAGI-3 has not been widely explored. 28 -30 We found that overexpression of MAGI-3 inhibited LPA-induced migration and invasion of colon cancer cells, whereas knockdown of MAGI-3 recapitulated the effect of NHERF-2 overexpression. Thus, these results show that MAGI-3 is a negative regulator of LPA 2 -mediated cellular functions, and provide evidence that PDZ domain-containing proteins play a critical role in regulating LPA 2 -mediated effects.
The PLC-PKC-Ca 2ϩ cascade is a major signaling pathway elicited by LPA 2 , which is potentiated by NHERF-2. 9 Unlike NHERF-2, we found that MAGI-3 attenuated PLC activity despite its binding of PLC-␤3. Importantly, the effect of MAGI-3 on PLC activity was not specific to LPA 2 , but also inhibited P2Y-mediated PLC activity, suggesting that MAGI-3 might be a negative regulator of PLC signaling by a broad range of GPCRs. The negative regulation by MAGI-3 could have risen from MAGI-3 simply displacing NHERF-2 and PLC-␤3 from LPA 2 . Indeed, MAGI-3 competed with NHERF-2 for both LPA 2 and PLC-␤3. However, deletion of NHERF-2 or MAGI-3 did not alter the amount of PLC-␤3 complexed with LPA 2 , suggesting that the change in PLC activity was not owing to inefficient complexing of PLC-␤3 by MAGI-3 with LPA 2 . Instead, the PDZ proteins facilitated LPA 2 coupling of different G proteins, without a significant effect on the total GTPase activity. In colon cancer cells, LPA 2 rapidly associated with G␣ q and G␣ 12 , but not with G␣ i , upon activation by LPA. NHERF-2 exclusively interacted with G␣ q and the presence of NHERF-2 led to a preferential enhancement of G␣ q -mediated downstream signaling by LPA 2 . In contrast to NHERF-2, MAGI-3 facilitated the association of LPA 2 with both G␣ q and G␣ 12 to divert LPA 2 -mediated signaling to G␣ q and G␣ 12 -dependent pathways, thereby lessening G␣ q -dependent activation of PLC. In support of MAGI-3 mediating G␣ 12 -dependent signaling, we showed previously that MAGI-3 potentiates LPA-induced RhoA activation in colon cancer cells. 11 In addition, it was shown recently that LPA 2 inhibits migration of pancreatic cancer cells via the G␣ 12 -RhoA pathway, 31 implying that that the activation of G␣ 12 -RhoA by MAGI-3 could contribute further to the inhibition of migratory response of colon cancer cells.
A number of GPCR-interacting proteins have been shown to regulate GPCR through multiple mechanisms involving recycling, targeting, or stability of receptor proteins. 8 NHERF-1, which is highly homologous to NH-ERF-2, associates with ␤ 2 -adrenergic receptor and -opioid receptor to promote recycling of the receptors, 32, 33 and postsynaptic density-95 interacts with ␤ 1 -adrenergic receptor to attenuate agonist-promoted receptor internalization. 34 In comparison, little is known about the receptor recycling or trafficking of LPA receptors except that LPA 1 is endocytosed rapidly in response to LPA in a dynamin2-and Rab5a-dependent mechanism. 35 We did not see any evidence for LPA-induced internalization of LPA 2 based on a luminometer-based cell surface assay, although rapid LPA 2 internalization and recycling might have escaped detection. Instead, our results showed that NHERF-2 enhanced the surface expression of LPA 2 , suggesting that LPA 2 is positioned and stabilized on plasma membrane through its interaction with NHERF-2. However, MAGI-3 showed no effect on the surface expression of LPA 2 . That NHERF-2, but not MAGI-3, alters LPA 2 surface stability might be explained by its ability to interact with the actin cytoskeletal network through the ezrin-radixin-moesin binding motif present at the carboxyl terminal region of NHERF-2. 36 Collectively, NH-ERF-2 facilitates migration and invasion of colon cancer cells by increasing surface expression of LPA 2 and potentiating the LPA 2 -G␣ q -PLC pathway ( Figure 5E ). In comparison, MAGI-3 diverts LPA 2 signaling to both G␣ q -PLC-3␤ and G␣ 12 -RhoA pathways.
Activation of NF-B often is linked to inflammation, but aggressive cancers and several cancer cell lines have constitutively active NF-B, and clinical evidence linking colon cancer and NF-B comes from epidemiologic studies. 37, 38 Similarly, transgenic expression of JNK in the intestine results in increased cell proliferation and migration, and JNK accelerates tumorigenesis in Apc Min/ϩ mice in part by cross-talk with the Wnt pathway. 39 In addition, nuclear localization of ␤-catenin in human colon carcinoma samples was paralleled by JNK activation. 40 In the present study, LPA-induced invasion of HCT116 cells was blocked by inhibition of NF-B or JNK, showing the critical role of NF-B and JNK in the invasion of colon cancer cells. The activation of NF-B and JNK by LPA is regulated by PLC-␤ as evidenced by silencing of MAGI-3 expression and inhibition by U73122. Importantly, we showed that the activation status of NF-B pathway in intestinal tumors of Apc Min/ϩ mice was attenuated markedly by the loss of LPA 2 expression. A similar reduction in IB␣ phosphorylation was observed in colitis-associated tumors in mice. However, the molecular mechanism of LPA 2 -mediated NF-B activation remains incompletely understood. Recent studies indicated that caspase recruit domain and MAGUK domain containing 3 plays an essential role in LPA-induced NF-B activation through coupling of Bcl10, an intermediate bridging factor, and Malt-1, a protein that stimulates inhibitor B kinase complex via interaction with Bcl10. 19, 41 In addition, it was shown that JNK signaling is regulated by Bcl10-dependent NF-B regulation in lymphocytes. 19 Therefore, it is an intriguing possibility that MAGI-3 may negatively regulate LPA-induced NF-B activation by interfering with the PKC-caspase recruit domain and MAGUK domain containing 3-Bcl10-MALT1 cascade.
The reciprocal roles of NHERF-2 and MAGI-3 on LPA 2 -induced effects on colon cancer cells correlate with the expression levels of NHERF-2 and MAGI-3 in human colon cancer tissues. Not only was the MAGI-3 expression lower in the tumor samples, the immunostaining scores of MAGI-3 correlated inversely with disease progression and lower scoring in late-stage adenocarcinomas, whereas NHERF-2 showed opposite results. Although it is tempting to suggest the expression levels of NHERF-2 and MAGI-3 as potential biomarkers of colon cancer, we have not fully established a causal link between these scaffold proteins and colon cancer and we await additional studies.
In summary, our data show that LPA 2 is dynamically regulated by 2 distinct PDZ proteins via modulation of G-protein coupling and receptor expression. The current studies reveal the potential relevance of PDZ interactions to colon cancer cell behaviors.
